DE60311995D1 - Neue purine derivate - Google Patents

Neue purine derivate

Info

Publication number
DE60311995D1
DE60311995D1 DE60311995T DE60311995T DE60311995D1 DE 60311995 D1 DE60311995 D1 DE 60311995D1 DE 60311995 T DE60311995 T DE 60311995T DE 60311995 T DE60311995 T DE 60311995T DE 60311995 D1 DE60311995 D1 DE 60311995D1
Authority
DE
Germany
Prior art keywords
compounds
disorders
unbranched
branched
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60311995T
Other languages
English (en)
Other versions
DE60311995T2 (de
Inventor
Peter Fischer
Michael Jarman
Edward Mcdonald
Bernard Nutley
Florence Raynaud
Stuart Wilson
Paul Workman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cyclacel Ltd
Cancer Research Technology Ltd
Original Assignee
Cyclacel Ltd
Cancer Research Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9942408&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60311995(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cyclacel Ltd, Cancer Research Technology Ltd filed Critical Cyclacel Ltd
Application granted granted Critical
Publication of DE60311995D1 publication Critical patent/DE60311995D1/de
Publication of DE60311995T2 publication Critical patent/DE60311995T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
DE60311995T 2002-08-15 2003-08-13 Neue purine derivate Expired - Lifetime DE60311995T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0219054.4A GB0219054D0 (en) 2002-08-15 2002-08-15 New purine derivatives
GB0219054 2002-08-15
PCT/GB2003/003554 WO2004016612A2 (en) 2002-08-15 2003-08-13 New purine derivatives

Publications (2)

Publication Number Publication Date
DE60311995D1 true DE60311995D1 (de) 2007-04-05
DE60311995T2 DE60311995T2 (de) 2007-10-31

Family

ID=9942408

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60311995T Expired - Lifetime DE60311995T2 (de) 2002-08-15 2003-08-13 Neue purine derivate

Country Status (17)

Country Link
US (2) US7582642B2 (de)
EP (1) EP1529047B8 (de)
JP (1) JP4723858B2 (de)
CN (1) CN1329393C (de)
AT (1) ATE354574T1 (de)
AU (1) AU2003267547B2 (de)
BR (1) BRPI0313477B8 (de)
CA (1) CA2492659C (de)
DE (1) DE60311995T2 (de)
DK (1) DK1529047T3 (de)
ES (1) ES2280773T3 (de)
GB (2) GB0219054D0 (de)
IL (1) IL166784A (de)
MX (1) MXPA05001843A (de)
NZ (1) NZ538135A (de)
PT (1) PT1529047E (de)
WO (1) WO2004016612A2 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2741881B1 (fr) * 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
GB0012528D0 (en) * 2000-05-23 2000-07-12 Univ Palackeho Triterpenoid derivatives
ATE301123T1 (de) * 2001-06-27 2005-08-15 Cyclacel Ltd 2,6,9-substituierte purinderivate und ihre verwendung bei der behandlung proliferativer krankheiten
GB0219054D0 (en) * 2002-08-15 2002-09-25 Cyclacel Ltd New purine derivatives
GB0219052D0 (en) * 2002-08-15 2002-09-25 Cyclacel Ltd New puring derivatives
CA2576159A1 (en) * 2004-08-27 2006-03-02 Cyclacel Limited Purine and pyrimidine cdk inhibitors and their use for the treatment of autoimmune diseases
EP1951307A2 (de) * 2005-11-11 2008-08-06 Cyclacel Limited Kombination aus einem cdk-hemmer und einem hdac-hemmer
US7560551B2 (en) 2006-01-23 2009-07-14 Amgen Inc. Aurora kinase modulators and method of use
EP1984353B1 (de) 2006-01-23 2015-12-30 Amgen, Inc Aurorakinasemodulatoren und anwendungsverfahren
US7868177B2 (en) 2006-02-24 2011-01-11 Amgen Inc. Multi-cyclic compounds and method of use
WO2008057280A1 (en) 2006-10-27 2008-05-15 Amgen Inc. Multi-cyclic compounds and methods of use
GB0706632D0 (en) * 2007-04-04 2007-05-16 Cyclacel Ltd New purine derivatives
GB0706633D0 (en) * 2007-04-04 2007-05-16 Cyclacel Ltd Combination
EP2137177B1 (de) 2007-04-05 2014-05-07 Amgen, Inc Aurora-kinasemodulatoren und verwendungsverfahren
KR101701109B1 (ko) 2007-10-05 2017-02-13 베라스템, 인코포레이티드 피리미딘 치환된 퓨린 유도체
EP2288611B1 (de) 2008-03-20 2013-05-15 Amgen Inc. Aurorakinasemodulatoren und anwendungsverfahren
US9126935B2 (en) 2008-08-14 2015-09-08 Amgen Inc. Aurora kinase modulators and methods of use
WO2010036380A1 (en) 2008-09-26 2010-04-01 Intellikine, Inc. Heterocyclic kinase inhibitors
JP5363800B2 (ja) * 2008-12-25 2013-12-11 ライオン株式会社 育毛剤組成物
CZ302122B6 (cs) * 2009-01-28 2010-10-20 Univerzita Palackého v Olomouci Substituované deriváty 6-(2-aminobenzylamino)purinu, jejich použití jako léciva a prípravky tyto slouceniny obsahující
EP2414362B1 (de) 2009-04-03 2014-06-11 Verastem, Inc. Pyrimidinsubstituierte purinverbindungen als kinase-(s)-inhibitoren
GB201001075D0 (en) 2010-01-22 2010-03-10 Cyclacel Ltd Crystalline forms
WO2013059634A1 (en) 2011-10-20 2013-04-25 The Regents Of The University Of California Use of cdk9 inhibitors to reduce cartilage degradation
EP2907514B1 (de) 2014-02-17 2019-10-23 Manros Therapeutics Purinderivatverbindungen zur medizinischen Verwendung
WO2016061144A1 (en) 2014-10-14 2016-04-21 The Regents Of The University Of California Use of cdk9 and brd4 inhibitors to inhibit inflammation
AU2018213119B2 (en) 2017-01-26 2021-10-28 Cyclacel Limited Process for preparing purine derivatives
EP3388432A1 (de) 2017-04-10 2018-10-17 Commissariat à l'Energie Atomique et aux Energies Alternatives Purinderivate zur verwendung als medikament und zur verwendung bei der behandlung neurodegenerativer oder neuroinflammatorischer erkrankungen
GB202000901D0 (en) * 2020-01-22 2020-03-04 Cyclacel Ltd Process
EP3901154A1 (de) * 2020-04-23 2021-10-27 Commissariat à l'énergie atomique et aux énergies alternatives Purinderivate als arzneimittel zur behandlung von neonataler hypoxie-ischämie-hirnverletzung und verwandten erkrankungen

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0874846B1 (de) 1995-11-01 2003-04-02 Novartis AG Purinderivate und verfahren zu ihrer herstellung
FR2741881B1 (fr) * 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
US5866702A (en) * 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
AU4920397A (en) 1996-10-11 1998-05-11 Chiron Corporation Purine inhibitors of glycogen synthase kinase 3 (gsk3)
AU735127B2 (en) * 1997-08-07 2001-06-28 Regents Of The University Of California, The Purine inhibitor of protein kinases, G proteins and polymerases
EP1042509A1 (de) 1997-12-24 2000-10-11 The Regents of the University of California Verfahren durch gebrauch an oligonukleotidarrays zum suchen von neuen kinase-inhibitoren
TR200002482T2 (tr) 1998-02-26 2002-10-21 Aventis Pharmaceuticals Inc. 6,9-Diikameli 2-(Trans-(4-Aminosiklohekzil) Amino)Pürinler
TR200102714T2 (tr) * 1999-02-01 2002-01-21 Cv Therapeutics, Inc. Sikline bağımlı kinaz 2 ve IkB-&'nın pürün inhibitörleri
US6627633B2 (en) * 1999-03-17 2003-09-30 Albany Molecular Research, Inc. 6-substituted biaryl purine derivatives as potent cyclin/CDK inhibitors and antiproliferative agents
US6969720B2 (en) * 1999-03-17 2005-11-29 Amr Technology, Inc. Biaryl substituted purine derivatives as potent antiproliferative agents
ATE301123T1 (de) * 2001-06-27 2005-08-15 Cyclacel Ltd 2,6,9-substituierte purinderivate und ihre verwendung bei der behandlung proliferativer krankheiten
US6812232B2 (en) * 2001-09-11 2004-11-02 Amr Technology, Inc. Heterocycle substituted purine derivatives as potent antiproliferative agents
US6667311B2 (en) * 2001-09-11 2003-12-23 Albany Molecular Research, Inc. Nitrogen substituted biaryl purine derivatives as potent antiproliferative agents
US20030229105A1 (en) * 2002-05-21 2003-12-11 Cyclacel Limited Treatment of autoimmune disorders
GB0219052D0 (en) * 2002-08-15 2002-09-25 Cyclacel Ltd New puring derivatives
GB0219054D0 (en) * 2002-08-15 2002-09-25 Cyclacel Ltd New purine derivatives
GB0706632D0 (en) * 2007-04-04 2007-05-16 Cyclacel Ltd New purine derivatives

Also Published As

Publication number Publication date
CA2492659A1 (en) 2004-02-26
IL166784A0 (en) 2006-01-15
EP1529047B8 (de) 2010-05-19
MXPA05001843A (es) 2005-04-19
NZ538135A (en) 2007-02-23
US8846696B2 (en) 2014-09-30
GB2392155A (en) 2004-02-25
GB0219054D0 (en) 2002-09-25
US20090325983A1 (en) 2009-12-31
CN1675211A (zh) 2005-09-28
AU2003267547B2 (en) 2009-06-18
BRPI0313477B8 (pt) 2021-05-25
DE60311995T2 (de) 2007-10-31
EP1529047B1 (de) 2007-02-21
CA2492659C (en) 2012-07-17
JP4723858B2 (ja) 2011-07-13
BRPI0313477B1 (pt) 2019-01-22
WO2004016612A3 (en) 2004-07-01
BR0313477A (pt) 2005-06-21
US20050256142A1 (en) 2005-11-17
ATE354574T1 (de) 2007-03-15
JP2006506341A (ja) 2006-02-23
GB0319256D0 (en) 2003-09-17
PT1529047E (pt) 2007-03-30
AU2003267547A1 (en) 2004-03-03
CN1329393C (zh) 2007-08-01
EP1529047A2 (de) 2005-05-11
WO2004016612A2 (en) 2004-02-26
ES2280773T3 (es) 2007-09-16
IL166784A (en) 2012-03-29
US7582642B2 (en) 2009-09-01
DK1529047T3 (da) 2007-03-19
GB2392155B (en) 2005-03-30

Similar Documents

Publication Publication Date Title
ATE354574T1 (de) Neue purine derivate
IL166783A0 (en) New purine derivatives
CY1116119T1 (el) Παραγωγα ισοξαζολο-πυριδινης
RS107504A (en) Benzofused heteroaryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compostions including the same, and methods for their use
DE602004017479D1 (de) Als neue antiangiogene mittel geeignete thienopyridinphenylacetamide und derivate davon
DE602005023015D1 (de) Indolderivate als viruzide
MX2009003410A (es) Fosfoindoles enantiomericamente puros como inhibidores de vih.
HRP20050390A2 (en) Substituted benzoxazinones and uses thereof
MX2007004183A (es) Derivados de benzoimidazol utiles como agentes antiproliferacion.
DK1117297T3 (da) Syntetiske analoger af ecteinascidin-743
AR065927A1 (es) Derivados de 5,6-dihidro-1h-piridin-2-ona
AR054102A1 (es) Derivados de fenil-piperazina-metanona. procesos de obtencion y composiciones farmaceuticas
CY1108632T1 (el) Παραγωγα της 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline για θεραπεια της στειροτητας
BRPI0409465A (pt) derivados de carboxamida como agentes antidiabéticos
MY139612A (en) Benzoxazine derivatives as 5-th6 modulators and uses thereof
RU2010107603A (ru) Производные n-(2-тиазолил)амида для лечения ожирения, диабетов и сердечно-сосудистых заболеваний
HUP0203739A2 (hu) A hatos-gyűrűn helyettesített biciklikus imidazo-3-il-amin-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
UY27685A1 (es) Indolil-urea derivados de tienopiridinas útiles como agentes antiangiogénicos, y procedimientos para su uso
ATE361749T1 (de) Benzthiazol-3 oxide zur behandlung von proliferativen störungen
ATE135206T1 (de) Arylalkylamine und -amide mit krampflösender und nervenschützender wirkung
DK1791811T3 (da) Aminoalkoholderivater
AR039319A1 (es) Imidazolinilmetil aralquilsulfonamidas
BG105126A (en) Tetrahydronaphthyridinyl-carboxamides have anti-convulsant activity
WO2004094396A3 (en) Dihydrothiazine prodrugs of thiazolium agents
HK1106502A1 (de)

Legal Events

Date Code Title Description
8364 No opposition during term of opposition